Following on from information provided to NICE by the company in September 2022, the appraisal of Ovarian, fallopian tube, peritoneal cancer (BRCA positive) – rucaparib, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1184 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in September 2022, the appraisal of Ovarian, fallopian tube, peritoneal cancer (BRCA positive) – rucaparib, was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 23 November 2017 | The company has been unable to source all the necessary evidence on comparator technologies to provide a submission that meets the requirements of the scope for this appraisal within the required timelines. Therefore the company and NICE have mutually agreed to put the appraisal on hold. Consequently the discussion of this appraisal at the committee meeting on 5 December 2017 will not take place. We will update you on our progress and next steps for this appraisal as soon as possible. |
| 07 July 2017 | In progress. This appraisal has started |
| 07 July 2017 | Invitation to participate |
| 21 April 2017 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual